tak 779 has been researched along with dapagliflozin in 1 studies
| Studies (tak 779) | Trials (tak 779) | Recent Studies (post-2010) (tak 779) | Studies (dapagliflozin) | Trials (dapagliflozin) | Recent Studies (post-2010) (dapagliflozin) |
|---|---|---|---|---|---|
| 118 | 1 | 35 | 1,478 | 368 | 1,407 |
| Protein | Taxonomy | tak 779 (IC50) | dapagliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 1 | Homo sapiens (human) | 1.1661 | |
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0022 | |
| Sodium/myo-inositol cotransporter 2 | Homo sapiens (human) | 0.38 | |
| Solute carrier family 5 member 4 | Homo sapiens (human) | 0.0014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
1 review(s) available for tak 779 and dapagliflozin
| Article | Year |
|---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |